It’s Prostate Cancer Awareness Month this month, one of the most common male cancers in the developed world. Prevalence rates vary widely across the globe. It is least common in South and East Asia, and more common in Europe, North America, Australia and New Zealand with rates in African Americans being the highest of all. However most people with Prostate Cancer do not end up dying from the disease and in many cases it can be safely monitored for a number of years before more active intervention is ever undertaken.
Health service providers also need to be mindful of global trends in a disease that has the potential to increase health burdens significantly in the next 10–20 years. Age is the most significant factor behind growth in the disease, and those countries with a large number of people reaching retirement age soon will clearly see the numbers of cases they have to deal with increase significantly. Genetics will also have an impact. Rapidly developing African countries such as Kenya, where the genetic potential for developing the disease is high and many more people are living into their 60s will be at particular risk. Whereas countries such as Thailand will have relatively more genetic protection.
There are other factors to consider though, such as the influence of social factors including increasing alcohol consumption and changes to diet. New technologies, including improved diagnostics, can also potentially influence trends in detection rates. Implementing screening programs for the disease will also serve to increase the numbers of patients with the disease who are detected earlier than they would have been otherwise, essentially causing a bump in incidence rates.
Similar to the way clinicians actively monitor prostate cancer patients under their caseload, Black Swan Analysts also continue to monitor market trends, closely following the production of any piece of healthcare analysis. Though our EpiomicTM Database now contains data on over 140 different diseases for up to 22 countries it is continually being added to. Not just from a primary disease perspective either, we are also continually increasing the granularity of data relating to both patient sub-groups and co-morbidities. Contact us to discuss how we can help you actively monitor any markets you’re interested in and provide you with insight into the trends.